The Annual General Meeting of Biovitrum resolved on 24 April 2008 to issue 284,000 series C shares to secure that the company can fulfill its commitment according to the performance based, long-term share program for 2008 (“Share Program 2008"). Furthermore, the Annual General Meeting resolved to authorize the board of directors to repurchase all issued series C shares for a price per share corresponding to the quota value of the Biovitrum share, i.e. in total SEK 156,000. The series C shares will thereafter be converted to common shares in the number that is required to secure delivery under the Share Program 2008.
The board of directors of Biovitrum has resolved to utilize the authorization for this purpose and to immediately repurchase all issued series C shares in accordance with the resolution by the Annual General Meeting on 24 April 2008. Biovitrum does currently not hold own shares.
About Biovitrum
Biovitrum is a pharmaceutical company with operations in Sweden and in the UK. The company markets a range of specialist pharmaceuticals. Using its expertise and experience Biovitrum takes scientific innovation all the way to the market and to specialist indication patients with significant medical need. Research expertise and capabilities include development and production of biotechnology therapeutics, as well as small molecule discovery and development. With revenues of approximately SEK 1.3 billion and around 500 employees, Biovitrum is a significant international specialty pharmaceutical player. Biovitrum’s share is listed on the OMX Nordic Exchange in Stockholm. For more information go to www.biovitrum.com
Biovitrum AB (publ) may be required to disclose the information provided herein pursuant to the Swedish Securities Markets Act. The information was provided for public release on December 23, 2008 at 08:30 a.m. CET.
